マンジャロをやめたら太る？リバウンドしない卒業のしかたを医師が解説

🔻Discount coupons available for Manjaro and other products 🔻Get a free ebook by Dr. Kiya on our official LINE account! 🎁 https://liff.line.me/2006164866-Z1zK3... Everyone will receive "Aiming for a 7kg Weight Loss in 3 Months! The Complete Roadmap to Medical Dieting" ✨ 🔸Recommended for those who: ・Seriously want to lose weight and become beautiful. ・Always rebound after dieting. ・Want to diet safely under a doctor's supervision. ・Are interested in popular medical diet drugs (Manjaro, GLP-1, etc.). ⭐️Channel Content ・Explained by a practicing doctor! The effects and risks of diet pills such as Manjaro. Key points for successful medical weight loss based on over 10,000 patients' weight loss treatments. Tips for diet management and preventing rebound weight gain. The inside story and latest trends in medical weight loss. ◆━━━━━━━━━━━━━━━━━━◆ ◼︎Dr. Kiya's Profile Takahiro Kiya Director, One Clinic Ebisu Representative Director, Medical Revolution Association Started his medical career in 2016. Provides a wide range of services including internal medicine, COVID-19 related testing, and cosmetic medicine (hair removal, etc.). Opened One Clinic Ebisu in 2021. Having personal experience using Manjaro and Rybelsus, he provides online consultations focusing on medical weight loss based on his own experience. ●Qualifications Held Medical License Occupational Health Consultant ◆━━━━━━━━━━━━━━━━━━◆ 【About Treatment】(Disclosure of Important Matters) 1. About Medical Treatment and Prescriptions Provided at Our Clinic At our clinic, we may prescribe type 2 diabetes medications (GLP-1 receptor agonists, SGLT2 inhibitors, metformin, etc.) as private medical treatment (for the purpose of obesity treatment) at the discretion of the physician. Since the use of these medications for the purpose of obesity treatment is not approved in Japan, this constitutes off-label use. We will make a comprehensive judgment based on the examination, test results, and medical history, and we cannot prescribe them to all patients. 2. Main Purpose and Indications of Treatment All of these medications are approved for the purpose of blood glucose control in type 2 diabetes. Use for obesity treatment will be carried out with sufficient explanation and consent, taking into account the approval status in Japan and overseas, and academic society guidelines. 3. Individual Differences in Effects, Side Effects, and Risks Taking or injecting these medications does not necessarily guarantee a certain level of weight loss. The effects vary greatly from person to person, and it is essential to use this treatment in conjunction with lifestyle changes, dietary therapy, and exercise therapy. Side effects such as hypoglycemia and gastrointestinal symptoms may occur; please consult a doctor immediately if you experience any discomfort. 4. Possibility of Tests and Additional Treatment Regular tests (blood, urine, etc.) may be necessary to continue treatment. Consultation fees, test fees, and additional medication costs may be incurred separately. 5. Precautions Regarding Private Medical Treatment Prescriptions for obesity treatment are not covered by health insurance (full self-payment). Because it is an off-label use, it may not be covered by the national drug side effect relief system. 6. Comparison with Other Treatments and Guarantees This treatment is merely one option, and we do not guarantee that it is superior to other medical institutions or other treatments. Treatment effectiveness and the risk of side effects vary from person to person, and the expected results are not always guaranteed. ────────────────── ◼GLP-1 Receptor Agonist (Oral Medication: Rybelsus) 【Treatment Details】 Rybelsus is an oral GLP-1 receptor agonist used to control blood glucose levels in type 2 diabetes. At our hospital, it may be prescribed for obesity treatment at the doctor's discretion (off-label use). Weight loss is expected due to its appetite-suppressing effect and sustained satiety. 【Dosage and Administration】 Take once daily before breakfast with 120 mL or less of water. Avoid eating, drinking, or taking other medications for 30 minutes after taking the medication (to maximize its effect). The initial dose is 3 mg, increased to 7 mg after one month, and can be increased up to 14 mg as needed. [Standard Costs] Rybelsus 3mg 30-day supply: ¥9,180 7mg 30-day supply: ¥17,420 14mg 30-day supply: ¥25,650 [Main Risks and Side Effects] Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), loss of appetite, acute pancreatitis (extremely rare) [Regarding the Use of Unapproved Drugs, etc.] Rybelsus is approved by the Ministry of Health, Labour and Welfare as a treatment for type 2 diabetes, but its prescription for the treatment of obesity is not approved in Japan. [Regarding the Source of Acquisition] This drug is procured from a domestic authori...